31 May 21 | Celltrion will launch Yuflyma® (biosimilar adalimumab) in the EU in June, as reported by the Korea Herald....
Pearce IP BioBlast®: w/e 04 June 2021
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
Pearce IP BioBlast®: w/e 28 May 2021
24 May 21 | IN | Zydus Cadila announced it has launched Ujvira (trastuzumab emtansine) in India. Ujvira is an antibody...
Pearce IP BioBlast®: w/e 21 May 2021
12 May 21 | Celltrion released its Q1 2020 financial results, reporting that YoY sales of Celltrion biosimilars...
Pearce IP BioBlast®: w/e 14 May 2021
11 May | US | Alvotech filed a federal lawsuit against AbbVie in the US District Court of the Eastern District of...
Unwrapping the (Patent) Box: much ado about nothing?
Australia's new 'Patent Box' tax break unlikely to incentivise medical and biotech R&D in Australia
On 11 May 2021, Treasurer Josh Frydenberg announced that the 2021-2022 Australian Federal Budget would introduce a...
Pearce IP BioBlast®: w/e 07 May 2021
01 May 21 | Samsung Bioepis announced a new study demonstrating the structural, physicochemical and biological...
NSW & Victoria compete to establish AU’s first mRNA manufacturing facility
In light of the COVID-19 vaccine supply shortages in Australia, it was refreshing to hear NSW Premier Gladys...
Pearce IP BioBlast®: w/e 30 April 2021
23 April | Boehringer Ingelheim announced results from a Ph III switching study of Cyltezo® (biosimilar adalimumab)...
Pearce IP BioBlast®: w/e 23 April 2021
15 April 21 | US | The Centre for Biosimilars reported a poster presented at AMCP 2021 shows a New York state Medicaid...
Galvanising your exclusive licence: take-home messages from recent case law
Questions to be answered by the High Court in the Lundbeck Appeal: Part Two
Recent decisions of the Australian Federal Court reinforce the need for exclusive patent licences to include all...
Pearce IP BioBlast®: w/e 16 April 2021
13 April 2021 | Purple Biotech announced it presented further preclinical data supporting the mechanism of action of...
Pearce IP BioBlast®: w/e 09 April 2021
06 April 2021 | PlantForm announced it has reached a collaborative research and development agreement with...
Pearce IP BioBlast®: w/e 02 April 2021
29 March 2021 | Samsung Bioepis announced on 29 March 2021 that it has launched Hadlima®, its 50mg/mL biosimilar...
Pearce IP BioBlast®: w/e 26 March 2021
24 March 2021 | EirGenix announced that its Ph III clinical trial of EG12014 (proposed trastuzumab biosimilar) has met...
When exclusive licensees have no rights to sue or recover damages during patent term extensions
A primer on the questions to be answered by the High Court in the Lundbeck Appeal
In February 2021, H. Lundbeck A/S (Lundbeck) was granted special leave by the High Court to appeal the 2020 Full...
Pearce IP BioBlast®: w/e 19 March 2021
15 March 2021 | Alvotech announced it has completed a second round of its US$100 million private placement. In the...